Pulse Biosciences, Inc. 8-K Summary
Business Context and Reporting Period
This Form 8-K reports the results of the 2025 Annual Meeting of Stockholders held by Pulse Biosciences, Inc. on December 9, 2025. The meeting was conducted virtually via live audio webcast.
Financial Metrics
This filing does not contain financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on corporate governance voting results.
Material Changes and Voting Results
Stockholders voted on four key proposals with the following outcomes:
- Election of Directors: All six nominees (Robert W. Duggan, Paul A. LaViolette, Manmeet S. Soni, Darrin R. Uecker, Richard A. van den Broek, and Mahkam Zanganeh, D.D.S.) were elected. Each received over 51 million votes "For" with minimal opposition.
- Ratification of Auditors: Stockholders ratified the appointment of Deloitte & Touche LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2025, with 63,077,669 votes "For".
- Executive Compensation (Say-on-Pay): Stockholders approved the compensation of named executive officers on a non-binding advisory basis with 52,270,567 votes "For".
- Frequency of Say-on-Pay Votes: Stockholders voted to hold future advisory votes on executive compensation every three years (32,308,346 votes) rather than annually or biennially.
Guidance, Outlook, and Risks
The filing does not provide management commentary, financial guidance, outlook, or specific risk factors. It is a standard disclosure of shareholder voting outcomes.
Key Facts for Investors to Verify
- Confirmation that all six director nominees were successfully elected to serve until the 2026 Annual Meeting.
- Verification that Deloitte & Touche LLP remains the independent auditor for the 2025 fiscal year.
- Noting the shareholder preference for triennial executive compensation advisory votes.
- Review of the specific vote counts to assess the level of shareholder support for management and the board.